Soleno Therapeutics has published the pivotal randomized withdrawal data for VYKAT XR (diazoxide choline extended-release) in the Journal of Clinical Endocrinology and Metabolism, reinforcing the evidence base behind the FDA’s 2025 approval as the first treatment for hyperphagia in Prader–Willi syndrome. The 16-week study enrolled 77 participants aged four and older who had completed prior Phase 3 studies and randomized them to continue VYKAT XR or switch to placebo. Hyperphagia, assessed by the Hyperphagia Questionnaire for Clinical Trials, worsened significantly in the placebo group versus continued treatment (p=0.0022). Weight and BMI z-score also trended in favor of VYKAT XR, with a least-squares mean weight difference of −1.6 kg versus placebo, and safety was comparable across arms with no serious adverse events in the active cohort.
The peer-reviewed validation matters well beyond publication prestige. For payers weighing caregiver-reported endpoints and behavioral outcomes in rare neurodevelopmental disorders, a controlled withdrawal signal of relapse on discontinuation offers a clinically intuitive narrative of treatment dependence and sustained benefit. The study also clarifies the product’s risk–benefit profile for prescribers: a once-daily oral therapy with manageable safety signals, but with the need to monitor for hyperglycemia and fluid retention. The strategic question is whether these data are sufficient to standardize coverage policies and embedding of disease-specific hyperphagia measures in routine care, or whether real-world outcomes will become the decisive lever for broad access.
For patients and caregivers in PWS, the publication underlines that hyperphagia is now addressable with an approved therapy rather than managed solely through environmental control and behavioral supervision. For clinicians, it lends urgency to building care pathways that integrate baseline and follow-up hyperphagia assessments, glucose and edema monitoring, and coordination across pediatric and adult endocrinology. For payers, the evidence highlights a shift from weight-centric metrics to disease-relevant endpoints tied to safety and caregiver burden, raising the bar for any competitor aiming to enter this space with non-weight outcomes that translate to utilization reductions and quality-of-life gains.
The competitive context remains relatively sparse. Prior efforts to pharmacologically manage PWS hyperphagia have faced efficacy and safety challenges, and the broader obesity field’s GLP-1 momentum has not yet produced a clear PWS-specific alternative. VYKAT XR thus occupies a first-mover position with a validated mechanism and a caregiver-reported endpoint package aligned to FDA precedent. That said, competitors and combination strategies may look to pair appetite circuits with metabolic agents, making head-to-head or add-on evidence a future battleground. Any such moves will need to meet the same bar of functional, patient- and caregiver-relevant outcomes that payers can operationalize in prior authorization criteria.
This publication also illustrates an emerging template in rare neurobehavioral drug development: leveraging randomized withdrawal designs, caregiver- and clinician-reported measures, and long-term exposure data to demonstrate maintenance of effect and practical safety. The commercial next steps are clear. Medical Affairs teams must drive guideline inclusion and HCP education on monitoring and adherence, while Evidence and HEOR leaders capture real-world reductions in food-seeking incidents, acute medical events, and caregiver time. The forward-looking question is whether Soleno can translate this clinical signal into durable coverage, expansion beyond the United States, and a data moat strong enough to fend off metabolic incumbents exploring PWS, or whether the field will evolve toward combination regimens that redefine the standard of care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
